Enliven Therapeutics, Inc. (NASDAQ: ELVN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
50.24
+1.12+2.28%
News
Up 2.3% — Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript (seekingalpha.com).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 33.56% | Shs Outstand | 71.44M | Perf Week | -10.65% |
| Market Cap | 3.59B | Forward P/E | - | EPS next Y | -2.26 | Insider Trans | -5.85% | Shs Float | 45.61M | Perf Month | -16.36% |
| Enterprise Value | 2.70B | PEG | - | EPS next Q | -0.43 | Inst Own | - | Short Float | 18.85% | Perf Quarter | 11.99% |
| Income | -104.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 5.98 | Perf Half Y | 84.37% |
| Sales | 0.00 | P/B | 4.01 | EPS next Y | -23.99% | ROA | -11.64% | Short Interest | 8.60M | Perf YTD | 226.23% |
| Book/sh | 12.53 | P/C | 4.01 | EPS next 5Y | - | ROE | -18.55% | 52W High | 62.32 -19.38% | Perf Year | 172.60% |
| Cash/sh | 12.53 | P/FCF | - | EPS past 3/5Y | - | ROIC | -13.88% | 52W Low | 14.79 239.69% | Perf 3Y | 205.04% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.42% 3.90% | Perf 5Y | 184.16% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 11.64% | Oper. Margin | 0.00% | ATR (14) | 2.42 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 64.07 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 29.83 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 64.07 | EPS Q/Q | 0.00% | SMA20 | -12.50% | Beta | 0.21 | Target Price | 76.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -10.79% | Rel Volume | 1.57 | Prev Close | 49.12 |
| Employees | 67 | LT Debt/Eq | -0.06 | Earnings | Nov 11 | SMA200 | 29.04% | Avg Volume | 1.23M | Price | 50.24 |
| IPO Date | Mar 12, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -26.56% - | Net Debt/EBITDA | 1.27 | Volume | 1,930,203 | Change | 2.28% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-18-26 | Initiated | Barclays | Overweight | $78 |
| Aug-18-26 | Reiterated | Mizuho | Outperform | $62 → $73 |
| Aug-06-26 | Reiterated | Stifel Nicolaus | $80 → $82 | |
| Aug-06-26 | Reiterated | Guggenheim | Buy | $80 → $78 |
| Aug-06-26 | Reiterated | Goldman Sachs | Buy | $67 → $80 |
| Jul-21-26 | Reiterated | Goldman Sachs | Buy | $59 → $67 |
| Jul-09-26 | Reiterated | HC Wainwright & Co. | Buy | $39 → $65 |
| Jul-01-26 | Reiterated | Stifel Nicolaus | $60 → $80 | |
| Jun-08-26 | Initiated | Stifel | Buy | $60 |
| Jun-02-26 | Reiterated | Mizuho | Outperform | $39 → $62 |
Latest News· Times ET
Sep-16-26
Sep-16-2602:31PM
Sep-03-26
05:48AM
Aug-31-26
Aug-31-2611:57PM
02:05PM
Aug-28-26
Aug-28-2612:12AM
Aug-18-26
Aug-18-2609:58AM
Aug-06-26
12:03AM
Aug-05-26
Aug-05-2612:05PM
Jul-31-26
Jul-31-2611:50PM
Jul-21-26
Jul-21-2604:40AM
Jul-09-26
Jul-09-2602:22AM
Jul-01-26
Jun-27-26
Jun-27-2611:36AM
Company
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 34 | 24 | 19 | — | — | — | — | — | — | |
| Research and Development | 86 | 81 | 65 | — | — | — | — | — | — | |
| Other Operating Expense | -1 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -120 | -105 | -84 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 16 | 16 | 12 | — | — | — | — | — | — | |
| Net Income Before Taxes | -104 | -89 | -72 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -104 | -89 | -72 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -104 | -89 | -72 | — | — | — | — | — | — | |
| Net Income | -104 | -89 | -72 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.83 | -1.89 | -2.01 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.83 | -1.89 | -2.01 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.83 | -1.89 | -2.01 | — | — | — | — | — | — | |
| EBITDA | -103 | -88 | -71 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 57 | 47 | 36 | — | — | — | — | — | — | |
| Market Capitalization | 878 | 1,058 | 498 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Aug 17 '26 | Sale | 58.58 | 6,018 | 352,551 | 40,036 | Aug 19 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Aug 17 '26 | Option Exercise | 2.48 | 5,000 | 12,400 | 30,000 | Aug 19 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Aug 17 '26 | Sale | 58.59 | 5,000 | 292,931 | 25,000 | Aug 19 |
| Derynck Mika K | Director | Aug 04 '26 | Option Exercise | 10.84 | 158,795 | 1,720,967 | 158,795 | Aug 06 |
| Derynck Mika K | Director | Aug 04 '26 | Sale | 60.21 | 158,795 | 9,561,587 | 0 | Aug 06 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Jul 17 '26 | Option Exercise | 2.48 | 1,072 | 2,659 | 52,072 | Jul 21 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Jul 17 '26 | Sale | 52.64 | 6,018 | 316,780 | 46,054 | Jul 21 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Jul 17 '26 | Option Exercise | 2.48 | 5,000 | 12,400 | 30,000 | Jul 21 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Jul 17 '26 | Sale | 52.67 | 5,000 | 263,374 | 25,000 | Jul 21 |
| Kunkel Lori Anne | Director | Jul 06 '26 | Sale | 50.49 | 10,000 | 504,903 | 41,884 | Jul 08 |
| ORBIMED ADVISORS LLC | 10% Owner | Jun 22 '26 | Sale | 45.36 | 860,123 | 39,014,045 | 219,405 | Jun 24 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Jun 17 '26 | Option Exercise | 2.48 | 6,018 | 14,925 | 57,018 | Jun 22 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | Jun 17 '26 | Sale | 43.80 | 6,018 | 263,577 | 51,000 | Jun 22 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Jun 17 '26 | Option Exercise | 2.48 | 5,000 | 12,400 | 30,000 | Jun 22 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | Jun 17 '26 | Sale | 43.80 | 5,000 | 219,017 | 25,000 | Jun 22 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.